The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles

Young, Michael D.

doi:10.1080/21645515.2019.1621148

Cited by 18 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…And according to the dose of different, in different time has a protective effect. [24] Active immunization: Vaccines. The approval and widespread use of the 1990s HAV vaccine has paved the way for the prevention of this disease.…”

Section: Discussionmentioning

confidence: 99%

Regional and Age Epidemiological Analysis of Hepatitis A Viral in China, 2004-2017

Xu¹,

Tang²

2021

Preprint

View full text Add to dashboard Cite

Background: To describe the prevalence features, including age, regions, morbidity and mortality of hepatitis A viral in China from 2004 to 2017 by searching the China Public Health Sciences Data Center with the keyword “Hepatitis A virus (HAV)”.Methods: In this study, HAV morbidity and mortality data were retrieved from China Public Health Science Data Center (CPHSD) using HAV as a keyword. HAV infection data from 2004 to 2017, HAV cases and HAV-related deaths were retrieved from 31 regions in China, except Taiwan, Hong Kong and Macau. SPSS 18 is used for statistical analysis. GraphPad Prism 5 is used to draw line graphs and histograms. Microsoft PowerPoint 2016 and Adobe Illustrator CS 6 are used for drawing geographically distributed China maps.Results: From 2004 to 2017, the rates of hepatitis A viral morbidity and mortality in China were keeping decrease annually (7.1997 and 3.0772 in 2004; 2.6430 and 0.2997 in 2010; 1.3679 and 0.2899 in 2017, respectively, 1/100,000) (p<0.001). The HAV infection rate of children (0-10 years old) was higher than that of the elderly (>50 years old) (p<0.001). The geographical distribution of HAV prevalence showed significant regional differences which showed that hepatitis A patients were more prevalent in Sichuan and Xinjiang provinces (averaged number >4,000/ year). HAV-related death does not differ much between regions (averaged number 0~2.1/ year)Conclusions: Our analysis of viral hepatitis A prevalence features over past 14 years suggests that the incidence and mortality of HAV are decreased annually in China.

show abstract

Section: Discussionmentioning

confidence: 99%

Regional and Age Epidemiological Analysis of Hepatitis A Viral in China, 2004-2017

Xu¹,

Tang²

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…195,196 Hyperimmune globulin is currently used for post-exposure prophylaxis in the treatment of several viral infections, including hepatitis B (HBV), rabies, tetanus toxin, varicella-zoster, rubella, measles, etc. 30,[197][198][199] The COVID-19 pandemic attracted much new research to develop therapeutic drug options, [200][201][202][203] including CPT 80,88,93,102,113,204 to treat patients as no specific medication is available. Initially, the US FDA approved and served EUA, 80,205 regarding CPT but later amended the earlier policy (September-2-2020).…”

Section: Discussionmentioning

confidence: 99%

<p>Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic</p>

Samad¹,

Sodunke²,

Banna³

et al. 2020

RMHP

View full text Add to dashboard Cite

The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare professionals are struggling to treat their patients based on nonspecific therapies. Amidst this uncertainty, convalescent plasma therapy (CPT) has appeared to be an interim adjuvant therapy for severely ill patients of COVID-19 until long-term clinical trial treatment options are available. Considering the transfusion-related hazards, especially lung injuries and microbial transmission, where sensitivity is not ensured, rigorous trials should be conducted to determine this therapy's efficacy. Moreover, the ratio of recovered cases to plasma donors is not satisfying, which questioning this therapy's availability and accessibility. Although some countries are making the treatment free, the attributable cost mandates a justification for its suitability and sustainability. Our article aimed to review the published facts and findings of CPT's effectiveness in lowering the mortality rate of COVID-19. This pandemic showed that healthcare systems worldwide need core reform. A unified global collaboration must align and coordinate to face the current pandemic and enhance world readiness for future outbreaks based on health equity and equality.

show abstract

“…Однако для производства и сертификации нового специфического иммуноглобулина, как и для производства новой вакцины, требуется достаточно длительное время. Крупнейшие мировые производители плазмы объединили свои усилия в CoVIg-9 Plasma Allianse для скорейшего получения и апробации такого гипериммунного иммуноглобулинового препарата, который позволил бы сделать терапию антителами против SARS-CoV-2 более стандартизированной и простой, но пока на фармацевтическом рынке его нет и неизвестно, когда он может появиться [35,36]. Для инициализации фракционирования и производства иммуноглобулина в России запас РП с высоким содержанием ВНА-антител должен быть значительным.…”

Section: Discussionunclassified

The Preparation of Convencent Plasma and Recruiting of Donors during the COVID-19 Pandemic

Kostin¹,

Петриков²,

Borovkova³

et al. 2020

Annals RAMS

View full text Add to dashboard Cite

Background. The pandemic of the new coronavirus infection has challenged the medical community for quickly finding and implementing effective methods of treatment. In the absence of a vaccine or specific therapy with proven effectiveness, the usage of convalescent plasma can be the one of perspective methods. An important aspect of this technology is the efficient and safe preparation of convalescent plasma. To date, in the world literature there are practically no publications about donor recruitment and the specifics of the preparation of convalescent plasma. Purpose of the research. Presentation of the experience of organizing a workflow for recruiting donors and stockpiling of convalescent plasma with a high titer of virus-neutralizing antibodies to SARS-CoV-2. Methods. The analysis of the work of the Blood Service of the Moscow Department of Health for stockpiling of COVID-19 convalescent plasma has been executed. In total it has been stockpiled 1240 doses. The normative documentation has been developed by a working group on the basis of the current federal legislation of Russian federation and been approved by the Moscow Department of Health. The titer of neutralizing antibodies (VNA) has been determined as the basic method for assessing the immunological viability of convalescent plasma. The main characteristics of donors, the characteristics of the disease course, the results of preliminary testing for the presence of specific antibodies by ELISA and CLIA methods has been compared with VNA titers in the stockpiled convalescent plasma. Results. Due to a Moscow Health Departments order No. 325 dated 01.04.2020 (a basic local regulatory document) it has been developed a regulation for the stockpiling, examination, storage, safety and transfering of fresh frozen pathogen-reduced plasma of COVID-19 convalescent donors to medical organizations of the Moscow Health Department. For arranging an interaction with donors it has been created a call-center. For effective preliminary selection, it has been formed a donor characteristics list, which has been combined with screening of specific antibodies by ELISA and CLIA methods. Conclusions. Developed a system of recruiting donors and procurement process of convalescent plasma for treatment СOVID-19, which includes the necessary regulations, algorithms for the selection and recruitment of donors, the registry of donors and recipients, algorithms, efficiency and safety of convalescent plasma.

show abstract

The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles

Cited by 18 publications

References 24 publications

Regional and Age Epidemiological Analysis of Hepatitis A Viral in China, 2004-2017

Regional and Age Epidemiological Analysis of Hepatitis A Viral in China, 2004-2017

<p>Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic</p>

The Preparation of Convencent Plasma and Recruiting of Donors during the COVID-19 Pandemic

Contact Info

Product

Resources

About